{"id":20217338,"updated":"2025-09-17T11:19:17Z","additionalIndexing":"2841","affairType":{"abbreviation":"Fra.","id":14,"name":"Fragestunde. Frage"},"author":{"councillor":{"code":2660,"gender":"f","id":1346,"name":"Moret Isabelle","officialDenomination":"Moret Isabelle"},"faction":{"abbreviation":"Fraktion RL","code":"RL","id":1,"name":"FDP-Liberale Fraktion"},"type":"author"},"deposit":{"council":{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N"},"date":"2021-03-10T00:00:00Z","legislativePeriod":51,"session":"5108"},"descriptors":[],"drafts":[{"consultation":{"resolutions":[{"category":{"id":3,"name":"Normal"},"council":{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N"},"date":"2021-03-15T00:00:00Z","text":"Schriftliche Beantwortung der Frage","type":83}]},"federalCouncilProposal":{"date":"2021-03-15T00:00:00Z"},"index":0,"links":[],"preConsultations":[],"references":[],"relatedDepartments":[{"abbreviation":"EDI","id":4,"name":"Departement des Innern","leading":true}],"states":[{"date":"\/Date(1615330800000+0100)\/","id":24,"name":"Im Rat noch nicht behandelt"},{"date":"\/Date(1615762800000+0100)\/","id":229,"name":"Erledigt"}],"texts":[]}],"language":"de","priorityCouncils":[{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N","priority":1}],"relatedAffairs":[],"roles":[{"councillor":{"code":2660,"gender":"f","id":1346,"name":"Moret Isabelle","officialDenomination":"Moret Isabelle"},"faction":{"abbreviation":"Fraktion RL","code":"RL","id":1,"name":"FDP-Liberale Fraktion"},"type":"author"}],"shortId":"21.7338","state":{"id":229,"name":"Erledigt","doneKey":"0","newKey":0},"texts":[{"type":{"id":14,"name":"Antwort BR \/ Büro"},"value":"<p>Die Antwort des Bundesrates existiert nur in französischer Sprache. (Bitte wechseln Sie auf der Homepage oben rechts die Sprache)<\/p>"},{"type":{"id":5,"name":"Eingereichter Text"},"value":"<p>L'article 3 al. 2 litt. i de la loi COVID19 ne permettrait-elle pas au Conseil fédéral d'obliger les pharmas suisses à provisoirement réaffecter une ligne de production à la production de l'un ou l'autre vaccin ou d'une des étapes de la fabrication ?<\/p><p>- Le Conseil fédéral a-t-il étudié cette question ?<\/p><p>- Pourquoi n'a-t-il pas appliqué cette disposition ?<\/p>"},{"type":{"id":1,"name":"Titel des Geschäftes"},"value":"2. Covid-19: Die Impfstoffproduktion unter Mitwirkung der Schweizer Pharmaindustrie hochfahren?"}],"title":"2. Covid-19: Die Impfstoffproduktion unter Mitwirkung der Schweizer Pharmaindustrie hochfahren?"}